Robert Azelby
Director · Autolus Therapeutics plc
Individual
- 2024
- Jul 1, 2026
- 7
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Robert Azelby files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Redmile Group, LLC - $19.64M in ADCT purchases and sales in the last 12 months
- Adam Crystal - $6.99M in TNGX purchases and sales in the last 12 months
- Barbara Weber - $374K in TNGX purchases and sales in the last 12 months
- Daniella Beckman - $127K in TNGX purchases and sales in the last 12 months
- Cintia Piccina - $16K in AUTL purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Robert Azelby?
Robert Azelby is a corporate insider, tracked as Director of Autolus Therapeutics plc (AUTL). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Robert Azelby last file a Form 4?
The most recent primary Form 4 on record is dated 1 July 2026, one of 7 filings going back to 2024.
